Recadin is used as a platelet aggregation inhibitor in patients following aortocoronary by-pass surgery, to prevent graft occlusion. Conditions where modification of platelet behavior is considered beneficial, including transient ischaemic attacks, secondary prevention of myocardial infarction and for prophylaxis against stroke, vascular occlusion and deep vein thrombosis.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
